Neuroendocrine Lung Cancer Mouse Models: An Overview

Area of Science:

• Oncology
• Translational Research
• Molecular Imaging

Background:

• Neuroendocrine lung tumors (NLTS) range from benign tumorlets to aggressive Small Cell Lung Carcinoma (SCLC), including Typical Carcinoids (TC), Atypical Carcinoids (AC), and Large Cell Neuroendocrine Carcinoma (LCNEC).
• Current treatments are suboptimal, with surgery for AC/TC and chemotherapy/immunotherapy for SCLC. Preclinical models are vital for research, especially for SCLC due to limited surgical material.
• The lack of early detection necessitates biomarker identification and molecular imaging development, particularly using somatostatin receptors.

Purpose of the Study:

• To review existing preclinical models for neuroendocrine lung tumors.
• To assess the impact of these models on understanding NLTS biology and subtype relationships.
• To evaluate the role of genomic analyses and molecular imaging in model development.

Main Methods:

• Review of reported preclinical models for neuroendocrine lung tumors.
• Analysis of genomic landscape data from human tumors.
• Evaluation of molecular imaging tools, including somatostatin receptor-based methods.

Main Results:

• Limited availability of preclinical models for most NLTS subtypes (except SCLC) presents a significant unmet need.
• Existing models have contributed to understanding NLTS biology and subtype interrelationships.
• Genomic insights and molecular imaging tools are influencing the development of new and improved models.

Conclusions:

• Development of diverse and relevant preclinical models is essential for advancing neuroendocrine lung tumor research.
• These models are critical for elucidating molecular mechanisms, identifying early detection biomarkers, and testing novel therapeutic strategies.
• Integrating genomic data and molecular imaging will accelerate the development and utility of preclinical models for NLTS.